Page last updated: 2024-09-05

lenalidomide and gossypol

lenalidomide has been researched along with gossypol in 3 studies

Compound Research Comparison

Studies
(lenalidomide)
Trials
(lenalidomide)
Recent Studies (post-2010)
(lenalidomide)
Studies
(gossypol)
Trials
(gossypol)
Recent Studies (post-2010) (gossypol)
3,5327252,8501,81047471

Protein Interaction Comparison

ProteinTaxonomylenalidomide (IC50)gossypol (IC50)
Mcl-1Homo sapiens (human)1.1916
Estrogen receptor 1Homo sapiens (human)2.5513
Prolyl endopeptidaseRattus norvegicus (Norway rat)0.28
Malate dehydrogenase, mitochondrialSus scrofa (pig)4.2683
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)0.86
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)0.86
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)0.86
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)0.86
Apoptosis regulator Bcl-2Homo sapiens (human)0.8268
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)0.86
Malate dehydrogenase, cytoplasmicSus scrofa (pig)4.7683
DNA-3-methyladenine glycosylaseHomo sapiens (human)3
Caspase-1Homo sapiens (human)1.23
DNA repair protein RAD52 homologHomo sapiens (human)5
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)2.274
BH3-interacting domain death agonistHomo sapiens (human)2.39
Bcl-2-like protein 1Homo sapiens (human)2.784
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)1.8192
L-lactate dehydrogenasePlasmodium falciparum (malaria parasite P. falciparum)2.64
Aspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)0.2725
L-lactate dehydrogenasePlasmodium falciparum CDC/Honduras4.562
L-lactate dehydrogenase B chainBos taurus (cattle)4.562
L-lactate dehydrogenasePlasmodium falciparum (malaria parasite P. falciparum)2.03
Inosine-5'-monophosphate dehydrogenase Pseudomonas aeruginosa PAO10.9
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)4.5709
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)3.2359

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Ailawadhi, S; Borrelo, I; Chanan-Khan, A; Chitta, K; Ersing, N; Khan, AN; Lee, KP; Manfredi, D; Masood, A; Miller, KC; Paulus, A; Sher, T1
Akhtar, S; Ansell, SM; Carr, J; Chanan-Khan, A; Chitta, K; Dispenzieri, A; Foran, J; Kumar, S; Mikhael, JR; Miller, KC; Paulus, A; Personett, D; Reeder, CB; Rivera, CE; Roy, V; Thompson, KJ1

Trials

1 trial(s) available for lenalidomide and gossypol

ArticleYear
Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.
    British journal of haematology, 2012, Volume: 157, Issue:1

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Female; Gene Expression Regulation, Leukemic; Gossypol; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thalidomide; Tumor Cells, Cultured

2012

Other Studies

2 other study(ies) available for lenalidomide and gossypol

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
    British journal of haematology, 2014, Volume: 164, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gossypol; Humans; Lenalidomide; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia

2014